Flood situation improves in northeast; three die in Manipur
The flood situation in the northeastern region improved in the last 24 hours but the toll continues.
According to Manipur's Directorate of Relief and Disaster Management, the State was dry on Friday, barring two areas, which experienced light rainfall. The rivers in receding mode, however, proved fatal for three persons, taking the death toll in rain-induced disasters across the region to 55.
Assam recorded the most fatalities with 21 victims of floods and landslides, followed by 12 in Arunachal Pradesh, six in Meghalaya and Mizoram, four in Manipur, three in Sikkim, two in Tripura, and one in Nagaland.
Nine persons, including a BJP Mahila Morcha leader from Odisha, are feared dead in Sikkim after the vehicle they were travelling in fell about 1,000 feet into the Teesta River on May 29. A Guwahati-based doctor, believed to have been caught in a landslide, has been missing in Arunachal Pradesh since May 31.
While 1.66 lakh people continue to be affected by floods in Manipur, mostly in the Imphal Valley, the number of flood-hit people in Assam reduced by about 1.2 lakh to 4.44 lakh across 18 districts.
A flood bulletin provided by the Assam State Disaster Management Authority said the Brahmaputra and four other rivers have been at certain stretches. 'We are currently operating 328 relief camps and relief distribution centres for 1.59 lakh people, who are yet to return home,' a spokesperson of the authority said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
12 minutes ago
- Economic Times
Intas Pharma completes acquisition of UDENYCA biosimilar for $558 million
Synopsis Intas Pharma finalized its acquisition of UDENYCA, a biosimilar to Neulasta, from Coherus Life Sciences for $558 million in December 2024. This acquisition strengthens Intas's position as a global leader in pegfilgrastim. Accord BioPharma, Intas's U.S. specialty business, will continue commercializing UDENYCA to reduce infection risk in cancer patients undergoing myelosuppressive chemotherapy. Agencies Intas Pharma has completed the acquisition of UDENYCA for $558 million, the company said in a release. UDENYCA is a biosimilar to Neulasta or Pegfilgrastim. It is used to treat side effects of radiation therapy in cancer patients such as recurrent infections. Intas acquired the biosimilar drug from California-based Coherus Life Sciences in December 2024.'This acquisition cements our position as a global leader in pegfilgrastim and allows us to further expand our specialty division across key international markets,' said Binesh Chudgar, Intas Pharma's chairman and managing Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, have acquired UDENYCA. With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, the company's release stated.'The completion of the UDENYCA acquisition marks a pivotal moment for Accord BioPharma, as it not only strengthens our market presence but broadens our capabilities as we endeavour to innovate and expand in the biosimilar space,' said Chrys Kokino, President, USA, Accord BioPharma.
Time of India
40 minutes ago
- Time of India
US appeals court upholds Arkansas law banning youth transgender care
Boston: A federal appeals court on Tuesday upheld an Arkansas law barring doctors from providing gender-affirming care including puberty blockers, hormones and surgery to transgender minors. The 8-2 decision by the St. Louis-based 8th U.S. Circuit Court of Appeals overturns a lower court ruling. It also follows the U.S. Supreme Court's June ruling holding that Tennessee's similar ban did not discriminate based on sex or transgender status. Citing that ruling, the 8th Circuit's majority agreed with Arkansas' Republican attorney general that the law did not violate transgender minors' equal protection rights under the U.S. Constitution. The 8th Circuit also went further than the Supreme Court, which has a 6-3 conservative majority, by deciding an unresolved legal issue of whether such bans violate parents' rights to provide appropriate medical care for their children. Lawyers for the plaintiffs -- a group of minors, parents and healthcare professionals -- argued the Arkansas law violated parents' due process rights under the U.S. Constitution's Fourteenth Amendment. But U.S. Circuit Judge Duane Benton, writing for the majority, cited a lack of historical support for the argument that parents have a right to obtain medical treatment for their children that a state legislature deems inappropriate. "This court finds no such right in this Nation's history and tradition," Benton wrote in an opinion joined by seven fellow appointees of Republican presidents. U.S. Circuit Judge Jane Kelly, an appointee of Democratic former President Barack Obama, dissented along with another judge, citing a "startling lack of evidence connecting Arkansas' ban on gender-affirming care with its purported goal of protecting children." "This is a tragically unjust result for transgender Arkansans, their doctors and their families," said Holly Dickson, executive director of the American Civil Liberties Union of Arkansas, which represented the plaintiffs. The decision overturns a ruling by a lower-court judge in 2023 who had declared the law unconstitutional after previously blocking it from taking effect in 2021. That year, Arkansas became the first U.S. state to ban gender-affirming care for minors. The Republican-led legislature passed the ban over the veto of then-Governor Asa Hutchinson, also a Republican.
Time of India
40 minutes ago
- Time of India
Cardinal Health to buy Solaris Health for $1.9 billion, posts weak results
Bengaluru: Cardinal Health said on Tuesday it will buy healthcare management firm Solaris Health for $1.9 billion in cash, as the drug distributor looks to expand its specialty business. Shares of Ohio-based Cardinal fell nearly 6% after it also reported fourth-quarter revenue slightly below estimates, hurt by the loss of contracts with UnitedHealth Group 's OptumRx, one of its largest customers. The company is buying Solaris through its unit called The Specialty Alliance. Cardinal will own about 75% of the healthcare management unit after the acquisition. The deal is worth about $2.4 billion in total including roughly $500 million in rollover equity from Solaris' physicians, as they chose to reinvest some of their equity into the new structure. Cardinal's specialty business includes costly medicines to treat complex conditions such as cancer and rheumatoid arthritis, and the deal gives it access to a network of community urologists across more than 750 providers in 14 states. Solaris provides administrative and management support services to healthcare providers in the urological field. Drug distributors , including Cardinal and rival McKesson , have been acquiring community care operators to gain access to specialty care providers and diversify the high-margin business. Cardinal struck a $1.12 billion deal last year to buy community cancer center operator Integrated Oncology Network to expand into cancer care. The company also reported fourth-quarter revenue that remained flat year-over-year. Its revenue of $60.16 billion came in shy of analysts' average estimate of $60.87 billion, according to data compiled by LSEG. Cardinal raised its 2026 profit forecast on Tuesday, betting on strong demand for costly specialty medicines and branded drugs. It expects annual adjusted per-share profit of $9.30 to $9.50, compared with $9.10 to $9.30 forecast previously. Adjusted profit per share of $2.08 narrowly beat estimates of $2.04.
